The Risks and Life-Saving Rewards of Biopharmaceutical Investment, With Josh Bilenker

America leads in biopharmaceutical innovation and drug
development, in large part due to effective life-science
policies, including significant federal investment in basic
research, robust intellectual property protections, effective
technology transfer policies, investment incentives, and,
importantly, drug pricing policies that enable companies to
invest in high-risk drug development. Rob and Jackie talk about
conducive environments for biopharmaceutical startups—and what
the federal government can do to maintain U.S.
competitiveness—with Josh Bilenker, CEO of Loxo Oncology at
Lilly. 


Mentioned:


Robert D. Atkinson, “Why Life-Sciences Innovation Is
Politically “Purple”—and How Partisans Get It Wrong” (ITIF,
February 2016). 

Stephen Ezell, “Ensuring U.S. Biopharmaceutical
Competitiveness” (ITIF, July 2020). 



Related:


Stephen Ezell, et al., “The Critical Role of
Biopharmaceutical Startups in Driving Life Sciences Innovation,”
ITIF webinar, July 16, 2020. 

Joe Kennedy, “The Link Between Drug Prices and Research on
the Next Generation of Cures” (ITIF, September 2019).